179 related articles for article (PubMed ID: 18079362)
1. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.
Bartlett NL; Younes A; Carabasi MH; Forero A; Rosenblatt JD; Leonard JP; Bernstein SH; Bociek RG; Lorenz JM; Hart BW; Barton J
Blood; 2008 Feb; 111(4):1848-54. PubMed ID: 18079362
[TBL] [Abstract][Full Text] [Related]
2. SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies.
Pinter-Brown LC
Expert Opin Investig Drugs; 2008 Dec; 17(12):1883-7. PubMed ID: 19012503
[TBL] [Abstract][Full Text] [Related]
3. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Forero-Torres A; Leonard JP; Younes A; Rosenblatt JD; Brice P; Bartlett NL; Bosly A; Pinter-Brown L; Kennedy D; Sievers EL; Gopal AK
Br J Haematol; 2009 Jul; 146(2):171-9. PubMed ID: 19466965
[TBL] [Abstract][Full Text] [Related]
4. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
Ansell SM; Horwitz SM; Engert A; Khan KD; Lin T; Strair R; Keler T; Graziano R; Blanset D; Yellin M; Fischkoff S; Assad A; Borchmann P
J Clin Oncol; 2007 Jul; 25(19):2764-9. PubMed ID: 17515574
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
Rothe A; Sasse S; Topp MS; Eichenauer DA; Hummel H; Reiners KS; Dietlein M; Kuhnert G; Kessler J; Buerkle C; Ravic M; Knackmuss S; Marschner JP; Pogge von Strandmann E; Borchmann P; Engert A
Blood; 2015 Jun; 125(26):4024-31. PubMed ID: 25887777
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.
Duvic M; Reddy SA; Pinter-Brown L; Korman NJ; Zic J; Kennedy DA; Lorenz J; Sievers EL; Kim YH
Clin Cancer Res; 2009 Oct; 15(19):6217-24. PubMed ID: 19789316
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.
Borchmann P; Schnell R; Fuss I; Manzke O; Davis T; Lewis LD; Behnke D; Wickenhauser C; Schiller P; Diehl V; Engert A
Blood; 2002 Nov; 100(9):3101-7. PubMed ID: 12384405
[TBL] [Abstract][Full Text] [Related]
14. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
Oflazoglu E; Stone IJ; Gordon KA; Grewal IS; van Rooijen N; Law CL; Gerber HP
Blood; 2007 Dec; 110(13):4370-2. PubMed ID: 17909075
[TBL] [Abstract][Full Text] [Related]
15. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
19. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
20. CD30: an important new target in hematologic malignancies.
Deutsch YE; Tadmor T; Podack ER; Rosenblatt JD
Leuk Lymphoma; 2011 Sep; 52(9):1641-54. PubMed ID: 21619423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
